General Moly, Inc.
GMO
GMO was delisted on the 30th of September, 2020.
7 hedge funds and large institutions have $6K invested in General Moly, Inc. in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 26 closing their positions.
77% less funds holding
Funds holding: 31 → 7 (-24)
92% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 26
99% less capital invested
Capital invested by funds: $681K → $6K (-$675K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$263K |
| 2 |
BlackRock
New York
|
-$178K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$61K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$54K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$29K |
GMO Hedge Fund Activity: Q4 2020 in Review
7 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in General Moly, Inc. (GMO) for Q4 2020, worth a combined $6K — down 99% from $681K a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of GMO and 2 opened new positions — a net loss of 24 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $263K sold.
- 7 institutional investors held General Moly, Inc. (GMO) as of Q4 2020, down from 31 in Q3 2020.
- Funds reported $6K of General Moly, Inc. stock for Q4 2020, down 99% quarter-over-quarter.
- 2 funds opened new General Moly, Inc. positions in Q4 2020 and 26 closed out, a net change of -24 holders.
- The largest General Moly, Inc. seller in Q4 2020 was Vanguard Group, an estimated $263K sold.
Based on aggregated 13F filings for Q4 2020.